Takano, Toshimi http://orcid.org/0000-0002-8417-5291
Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Ito, Mitsuya
Inoue, Kenichi
Tanabe, Yuko http://orcid.org/0000-0001-9279-5952
Kawaguchi, Kousuke
Yasojima, Hiroyuki
Bando, Hiroko http://orcid.org/0000-0002-7361-3647
Nakamura, Rikiya http://orcid.org/0000-0002-4349-9046
Yamanaka, Takashi
Ishida, Kazushige http://orcid.org/0000-0001-7727-8869
Aruga, Tomoyuki http://orcid.org/0000-0003-3442-8972
Yanagita, Yasuhiro
Tokunaga, Eriko
Aogi, Kenjiro
Ohno, Shinji
Kasai, Hiroi
Kataoka, Tatsuki R. http://orcid.org/0000-0003-3095-8976
Morita, Satoshi
Toi, Masakazu
Clinical trials referenced in this document:
Documents that mention this clinical trial
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
https://doi.org/10.1007/s10549-020-05524-6
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
https://doi.org/10.1007/s10549-024-07333-7
Funding for this research was provided by:
Japan Breast Cancer Research Group
Article History
Received: 31 October 2023
Accepted: 8 April 2024
First Online: 20 May 2024
Declarations
:
: Takano T received honoraria for lectures (personal) from Chugai Pharmaceutical, Daiichi Sankyo, and Eli Lilly Japan. Masuda N received grants (to institution) from Chugai Pharmaceutical, Eli Lilly Japan, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis Pharma, Sanofi, Kyowa Kirin and Nippon Kayaku; received honoraria (personal) from Chugai Pharmaceutical, Pfizer, AstraZeneca, Eli Lilly Japan and Daiichi Sankyo; is a representative of Board of Directors (unpaid) for Japan Breast Cancer Research Group (JBCRG), and a member of Board of Directors (unpaid) for Japanese Breast Cancer Society (JBCS). Inoue K received grants (to institution) from MSD, Daiichi Sankyo, Chugai Pharmaceutical, AstraZeneca, Sanofi, Astellas, Ono Pharmaceutical, Takeda Pharmaceutical, Eisai, Gilead, and Novartis Pharma. Kawaguchi K received grants (to institution) from Terumo, Astellas, Eli Lilly Japan, Kyoto Breast Cancer Research Network (KBCRN) and Daiichi Sankyo; received consulting fees (personal) from Becton Dickinson Japan; received honoraria (personal) from Eisai, Chugai Pharmaceutical, Takeda Pharmaceutical, Daiichi Sankyo and MSD. Yasojima H received honoraria (personal) from Eisai, Chugai Pharmaceutical, AstraZeneca, Eli Lilly Japan, Daiichi Sankyo and Pfizer. Bando H received honoraria (personal) from Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Eisai, Kyowa Kirin, AstraZeneca, Pfizer and MSD; is a member of Advisory Board for Chugai Pharmaceutical and Eli Lilly Japan. Nakamura R received honoraria (personal) from Eli Lilly Japan, AstraZeneca, Daiichi Sankyo and Chugai Pharmaceutical. Yamanaka T received honoraria for lectures (personal) from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Kyowa Kirin, Novartis Pharma, Pfizer and Taiho Pharmaceutical. Aruga T received honoraria (personal) from Pfizer, Chugai Pharmaceutical, AstraZeneca, Eli Lilly Japan and Kyowa Kirin. Tokunaga E received honoraria (personal) from Eli Lilly Japan, Daiichi Sankyo and AstraZeneca. Aogi K received grants (to institution) from Chugai Pharmaceutical, Eisai and Takeda Pharmaceutical; received honoraria (personal) from Eisai, Chugai Pharmaceutical, AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Daiichi Sankyo and Pfizer. Ohno S received honoraria (personal) from Chugai Pharmaceutical, MSD, Eli Lilly Japan and Nippon Kayaku. Morita S received honoraria (personal) from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly Japan, MSD, Pfizer, Taiho Pharmaceutical, Novartis Pharma. Toi M received grants (to institution) from Kansai Med Net, AFI technology, Eisai, Astellas, Nippon Kayaku, Taiho Pharmaceutical, Sanwa Syurui, Shimadzu, Chugai Pharmaceutical, Pfizer, Yakult, Zene, AstraZeneca, and JBCRG; received consulting fees (personal) for Advisory Board from Bertis, Eli Lilly Japan and Daiichi Sankyo; received honoraria for chair (personal) from AstraZeneca, MSD, Eisai, Devicor Medical Japan, Kyowa Kirin, Daiichi Sankyo, Eli Lilly Japan, Nippon Kayaku, Taiho Pharmaceutical, Exact Science, Shimadzu, Chugai Pharmaceutical, Pfizer, Yakult and Sysmex; is a chairman (unpaid) of JBCS, a member of Board of Directors (unpaid) for JBCRG and KBCRN, and an associate editor of Breast Cancer Research and Treatment, Science Reports and Cancer Science. Ito M, Tanabe Y, Ishida K, Yanagita Y, Kasai H, and Kataoka TR have nothing to declare associated with this manuscript.
: The study was conducted in compliance with the Declaration of Helsinki and relevant ethical guidelines for clinical and epidemiological studies. Furthermore, approval from an ethics committee was obtained at each institution at the start of both the Neo-peaks study and the present follow-up study.
: Informed consent to participate in the Neo-peaks study was obtained from all patients at the time of enrollment.